DK2289533T3 - Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider - Google Patents

Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider

Info

Publication number
DK2289533T3
DK2289533T3 DK10177960.1T DK10177960T DK2289533T3 DK 2289533 T3 DK2289533 T3 DK 2289533T3 DK 10177960 T DK10177960 T DK 10177960T DK 2289533 T3 DK2289533 T3 DK 2289533T3
Authority
DK
Denmark
Prior art keywords
peptides
carendothelial
well
growth factor
factor receptor
Prior art date
Application number
DK10177960.1T
Other languages
Danish (da)
English (en)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DK2289533T3 publication Critical patent/DK2289533T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
DK10177960.1T 2005-02-28 2006-02-17 Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider DK2289533T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
EP06714491A EP1855707B1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
DK2289533T3 true DK2289533T3 (da) 2013-12-02

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10177960.1T DK2289533T3 (da) 2005-02-28 2006-02-17 Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
DK09007549.0T DK2095822T3 (da) 2005-02-28 2006-02-17 Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
DK06714491.5T DK1855707T3 (da) 2005-02-28 2006-02-17 Epitoppeptider afledt af vaskulær endothelial vækstfaktorreceptor 1 samt vacciner, der indeholder disse peptider

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK09007549.0T DK2095822T3 (da) 2005-02-28 2006-02-17 Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
DK06714491.5T DK1855707T3 (da) 2005-02-28 2006-02-17 Epitoppeptider afledt af vaskulær endothelial vækstfaktorreceptor 1 samt vacciner, der indeholder disse peptider

Country Status (10)

Country Link
US (4) US7919099B2 (enExample)
EP (4) EP1855707B1 (enExample)
JP (3) JP4931154B2 (enExample)
CY (1) CY1112867T1 (enExample)
DK (3) DK2289533T3 (enExample)
ES (3) ES2435650T3 (enExample)
PL (3) PL2095822T3 (enExample)
PT (3) PT2289533E (enExample)
SI (3) SI2095822T1 (enExample)
WO (1) WO2006093030A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375299T3 (es) * 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
CN101678065A (zh) * 2007-02-16 2010-03-24 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
ES2230542T3 (es) 1993-03-25 2005-05-01 MERCK & CO., INC. Inhibidor del factor de crecimiento celular endotelial vascular.
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
JP4035845B2 (ja) 2001-12-10 2008-01-23 株式会社グリーンペプタイド 腫瘍抗原
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
ES2375299T3 (es) * 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
PL1855707T3 (pl) 2012-08-31
ES2435650T3 (es) 2013-12-20
JP2008531463A (ja) 2008-08-14
WO2006093030A1 (en) 2006-09-08
US7919099B2 (en) 2011-04-05
PT2289533E (pt) 2013-12-10
JP4931154B2 (ja) 2012-05-16
CY1112867T1 (el) 2016-04-13
PT1855707E (pt) 2012-05-25
SI2095822T1 (sl) 2013-12-31
ES2385396T3 (es) 2012-07-24
SI1855707T1 (sl) 2012-07-31
JP2012102105A (ja) 2012-05-31
US20140186381A1 (en) 2014-07-03
PT2095822E (pt) 2013-12-09
JP2010265269A (ja) 2010-11-25
DK1855707T3 (da) 2012-07-16
DK2095822T3 (da) 2014-01-13
EP2289533B1 (en) 2013-09-18
US20110250219A1 (en) 2011-10-13
EP2095822A1 (en) 2009-09-02
US8257711B2 (en) 2012-09-04
ES2442294T3 (es) 2014-02-11
EP1855707A1 (en) 2007-11-21
PL2095822T3 (pl) 2014-03-31
HK1152873A1 (en) 2012-03-16
JP5789820B2 (ja) 2015-10-07
EP2289533A1 (en) 2011-03-02
SI2289533T1 (sl) 2013-11-29
EP2095822B1 (en) 2013-10-16
US20120294877A1 (en) 2012-11-22
US20090214581A1 (en) 2009-08-27
HK1133601A1 (en) 2010-04-01
JP4843095B2 (ja) 2011-12-21
PL2289533T3 (pl) 2014-02-28
EP1855707B1 (en) 2012-04-04
US8663647B2 (en) 2014-03-04
EP2289532A1 (en) 2011-03-02
HK1110529A1 (en) 2008-07-18

Similar Documents

Publication Publication Date Title
EP1548032A4 (en) KDR-PEPTIDES AND VACCINES CONTAINING THEM
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
EP2476699A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
MX2009007261A (es) Vacuna de peptido foxp3.
MX2010005816A (es) Epítopos de péptido de stat3.
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
CY1114720T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide